company background image
CTMX logo

CytomX Therapeutics NasdaqGS:CTMX Stock Report

Last Price

US$1.38

Market Cap

US$106.0m

7D

-2.8%

1Y

-22.9%

Updated

19 Jul, 2024

Data

Company Financials +

CytomX Therapeutics, Inc.

NasdaqGS:CTMX Stock Report

Market Cap: US$106.0m

CytomX Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CytomX Therapeutics
Historical stock prices
Current Share PriceUS$1.38
52 Week HighUS$5.85
52 Week LowUS$1.04
Beta1.06
11 Month Change6.98%
3 Month Change-17.37%
1 Year Change-22.91%
33 Year Change-75.14%
5 Year Change-86.44%
Change since IPO-89.30%

Recent News & Updates

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Recent updates

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Checking In On CytomX Therapeutics

Jun 13

Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Jun 10
Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

CytomX EPS beats by $0.06, misses on revenue

May 06

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Mar 25
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Shareholder Returns

CTMXUS BiotechsUS Market
7D-2.8%-0.1%-1.9%
1Y-22.9%11.1%19.4%

Return vs Industry: CTMX underperformed the US Biotechs industry which returned 12% over the past year.

Return vs Market: CTMX underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is CTMX's price volatile compared to industry and market?
CTMX volatility
CTMX Average Weekly Movement63.7%
Biotechs Industry Average Movement10.7%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: CTMX's share price has been volatile over the past 3 months.

Volatility Over Time: CTMX's weekly volatility has increased from 33% to 64% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008121Sean McCarthywww.cytomx.com

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.

CytomX Therapeutics, Inc. Fundamentals Summary

How do CytomX Therapeutics's earnings and revenue compare to its market cap?
CTMX fundamental statistics
Market capUS$105.97m
Earnings (TTM)US$16.53m
Revenue (TTM)US$119.18m

6.5x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTMX income statement (TTM)
RevenueUS$119.18m
Cost of RevenueUS$0
Gross ProfitUS$119.18m
Other ExpensesUS$102.65m
EarningsUS$16.53m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.21
Gross Margin100.00%
Net Profit Margin13.87%
Debt/Equity Ratio0%

How did CTMX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.